Vanda Pharmaceuticals - Stock Price History | VNDA

Historical daily share price chart and data for Vanda Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Vanda Pharmaceuticals as of September 27, 2021 is 17.58.
  • The all-time high Vanda Pharmaceuticals stock closing price was 31.67 on January 24, 2007.
  • The Vanda Pharmaceuticals 52-week high stock price is 21.86, which is 24.3% above the current share price.
  • The Vanda Pharmaceuticals 52-week low stock price is 9.50, which is 46% below the current share price.
  • The average Vanda Pharmaceuticals stock price for the last 52 weeks is 15.86.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Vanda Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 11.6063 16.1800 16.7950 7.5000 13.1400 -19.93%
2019 16.8732 27.0200 31.0500 12.2700 16.4100 -37.20%
2018 19.3574 15.6000 31.4700 13.9500 26.1300 71.91%
2017 15.0631 15.6000 18.8500 12.8500 15.2000 -4.70%
2016 11.8836 8.9900 17.6300 7.2300 15.9500 71.32%
2015 11.0722 14.5800 14.5800 8.1850 9.3100 -34.99%
2014 13.1050 12.6000 18.7100 8.8100 14.3200 15.39%
2013 7.9223 3.7100 14.5860 3.6800 12.4100 235.41%
2012 4.2397 4.7200 5.4600 3.0300 3.7000 -22.27%
2011 6.6188 9.9800 9.9800 4.3600 4.7600 -49.68%
2010 8.5654 11.6700 12.3800 6.2200 9.4600 -15.91%
2009 8.2374 0.5500 16.0500 0.5500 11.2500 2150.00%
2008 2.8170 6.5000 6.5000 0.5000 0.5000 -92.73%
2007 18.6681 24.8300 31.6700 6.5600 6.8800 -72.09%
2006 11.4476 9.6800 26.1700 7.9900 24.6500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.978B $0.248B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29